Table 3 Favorable response (complete plus partial) by patient subgroup (N = 101)
Variable | Favorable response % (n/N) [95%CI] |
|---|---|
Overall | 56.4 (57/101) [46.7; 66.1] |
Probable aspergillosis | 56.3 (40/71) [44.0; 68.1] |
Proven aspergillosis | 56.7 (17/30) [37.4; 74.5] |
Combination therapy | 56.3 (9/16) [29.9; 80.2] |
First line | 60.0 (3/5) [14.6; 94.7] |
Second Line | 54.6 (6/11) [23.4; 83.3] |
Monotherapy | 56.5 (48/85) [45.3; 67.2] |
First line | 60.0 (9/15) [32.3; 83.7] |
Second Line | 55.7 (39/70) [43.3; 67.6] |
First-line therapy | 60.0 (12/20) [36.1; 80.9] |
Salvage therapy | 55.6 (45/81) [44.1; 66.6] |
Culture examination performed | 62.3 (38/61) [50.1; 74.5] |
Positive | 55.6 (15/27) [36.9; 76.6] |
Negative | 67.6 (23/34) [49.5; 82.6] |
Neutropenic status at start of caspofungin therapy | |
ANC < 500 cells/μL | 52.5 (31/59) [39.1; 65.7] |
ANC > = 500 cells/μL | 61.9 (26/42) [45.6; 76.4] |
Risk factors | |
Active malignancy | 51.9 (41/79) [40.4; 63.3] |
AIDS/HIV infection | 66.7 (2/3) [9.4; 99.2] |
Bone marrow/stem cell transplantation | 53.6 (15/28) [33.9; 72.5] |
• Autologous HSCT | 40.0 (2/5) [5.3; 85.3] |
• Allogeneic HSCT | 56.5 (13/23) [34.5; 76.8] |
Diabetes mellitus | 57.1 (8/14) [28.9; 82.3] |
Immunosuppressive medication | 60.8 (45/74) [48.8; 72.0] |
Neutropenia at the time of hospitalization | 53.0 (35/66) [40.3; 65.4] |
Prior fungal colonization | 61.1 (11/18) [35.7; 82.7] |
Organ transplantation | 75.0 (6/8) [34.9; 96.8] |